title: Effects exerted by otilonium bromide administration on precipitated opioid withdrawal syndrome in rats.
abstract: An opioid withdrawal syndrome was induced in rats by repeated morphine administration and final naloxone injection. The withdrawal causes alteration of several physiological signs. The aim of the study was to prevent the altered physiological profiles by utilising otilonium bromide. Morphine was administered in three daily i.p. injections for 4 days at doses of 9, 16 and 25 mg/kg (1st day), 25, 25 and 50 mg/kg (2nd day), 50, 50 and 50 mg/kg (3rd day) and 50, 50 and 100 mg/kg (4th day). Naloxone was injected (30 mg/kg) i.p. 180 min after the last morphine injection. Otilonium bromide was administered orally at 0, 2, 4 and 8 mg/kg, 120 min before the naloxone administration. Signs like faecal and urine excretion, rectal temperature and pain threshold levels, salivation, jumping and wet dog shakes were affected in different ways. Notably the administration of otilonium bromide in rats receiving morphine together with naloxone decreased the intensity of certain withdrawal symptoms, such as excretion of faeces, wet dog shake behaviour, and elevated the nociceptive threshold values. The effects exhibited by otilonium bromide administration may be explained through its calcium antagonist activity interfering with a mechanism involved in the regulation of these previously mentioned withdrawal symptoms. The use of this drug is thus suggested as a possible control of some acute opioid withdrawal signs in heroin addicts.
authors.affiliation: Department of Pharmacology, Chemotherapy and Medical Toxicology, Milano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pinelli
authors.forename: S
authors.initials: S
authors.lastname: Trivulzio
authors.forename: S
authors.initials: S
authors.lastname: Vignati
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002118:Calcium / Q000037:antagonists & inhibitors; D004285:Dogs; D005769:Gastrointestinal Motility / Q000187:drug effects; D008297:Male; D009020:Morphine / Q000008:administration & dosage* / Q000633:toxicity / Q000652:urine; D009270:Naloxone / Q000008:administration & dosage* / Q000633:toxicity / Q000652:urine; D010276:Parasympatholytics / Q000008:administration & dosage / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage* / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D012007:Rectum / Q000502:physiology; D012463:Saliva / Q000187:drug effects / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000378:metabolism* / Q000503:physiopathology / Q000652:urine; D014554:Urination / Q000187:drug effects
chemical_list: D010276:Parasympatholytics; D000644:Quaternary Ammonium Compounds; C013934:octylonium; D009270:Naloxone; D009020:Morphine; D002118:Calcium